1042 related articles for article (PubMed ID: 16916931)
1. A2A adenosine receptor protects tumors from antitumor T cells.
Ohta A; Gorelik E; Prasad SJ; Ronchese F; Lukashev D; Wong MK; Huang X; Caldwell S; Liu K; Smith P; Chen JF; Jackson EK; Apasov S; Abrams S; Sitkovsky M
Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13132-7. PubMed ID: 16916931
[TBL] [Abstract][Full Text] [Related]
2. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
3. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
Sitkovsky MV; Kjaergaard J; Lukashev D; Ohta A
Clin Cancer Res; 2008 Oct; 14(19):5947-52. PubMed ID: 18829471
[TBL] [Abstract][Full Text] [Related]
5. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.
Ohta A; Ohta A; Madasu M; Kini R; Subramanian M; Goel N; Sitkovsky M
J Immunol; 2009 Nov; 183(9):5487-93. PubMed ID: 19843934
[TBL] [Abstract][Full Text] [Related]
6. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor.
Eini H; Frishman V; Yulzari R; Kachko L; Lewis EC; Chaimovitz C; Douvdevani A
Biochem Pharmacol; 2015 Nov; 98(1):110-8. PubMed ID: 26296573
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
8. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.
Choukèr A; Thiel M; Lukashev D; Ward JM; Kaufmann I; Apasov S; Sitkovsky MV; Ohta A
Mol Med; 2008; 14(3-4):116-23. PubMed ID: 18163162
[TBL] [Abstract][Full Text] [Related]
9. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
10. A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
Young A; Ngiow SF; Gao Y; Patch AM; Barkauskas DS; Messaoudene M; Lin G; Coudert JD; Stannard KA; Zitvogel L; Degli-Esposti MA; Vivier E; Waddell N; Linden J; Huntington ND; Souza-Fonseca-Guimaraes F; Smyth MJ
Cancer Res; 2018 Feb; 78(4):1003-1016. PubMed ID: 29229601
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
Steingold JM; Hatfield SM
Front Immunol; 2020; 11():570041. PubMed ID: 33117358
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible.
Ohta A; Madasu M; Subramanian M; Kini R; Jones G; Choukèr A; Ohta A; Sitkovsky M
Int Immunol; 2014 Feb; 26(2):83-91. PubMed ID: 24150242
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
[TBL] [Abstract][Full Text] [Related]
14. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
15. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
Sun C; Wang B; Hao S
Front Immunol; 2022; 13():837230. PubMed ID: 35386701
[TBL] [Abstract][Full Text] [Related]
16. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
17. Extracellular adenosine controls NKT-cell-dependent hepatitis induction.
Subramanian M; Kini R; Madasu M; Ohta A; Nowak M; Exley M; Sitkovsky M; Ohta A
Eur J Immunol; 2014 Apr; 44(4):1119-29. PubMed ID: 24448964
[TBL] [Abstract][Full Text] [Related]
18. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
[TBL] [Abstract][Full Text] [Related]
19. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
Hatfield SM; Sitkovsky M
Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
[TBL] [Abstract][Full Text] [Related]
20. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
